473 related articles for article (PubMed ID: 21407003)
1. Multidrug-resistant gram-negative infections. Bringing back the old.
Chan-Tompkins NH
Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
[TBL] [Abstract][Full Text] [Related]
2. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
Giamarellou H
Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
[TBL] [Abstract][Full Text] [Related]
5. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
7. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
Vergidis PI; Falagas ME
Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
11. New information about the polymyxin/colistin class of antibiotics.
Molina J; Cordero E; Pachón J
Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Karakonstantis S; Kritsotakis EI; Gikas A
Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Garrison MW; Mutters R; Dowzicky MJ
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
[TBL] [Abstract][Full Text] [Related]
15. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
19. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
Huang J; Tang YQ; Sun JY
Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
[TBL] [Abstract][Full Text] [Related]
20. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
